65 Yaş Üstü COVID-19 Hastalarında CoronaVac Aşısının Etkinliğinin Değerlendirilmesi

Year 2022, Volume: 15 Issue: 3, 269 - 274, 30.12.2022

Aslı Şener , Arife Erdoğan , Hayriye Gönüllü

https://doi.org/10.52976/vansaglik.1150670

Abstract

Özet: 2019 yılı Aralık ayından başlayarak tüm dünyayı etkisi altına alan Covid-19 pandemisinde alınmış olan çeşitli önlemler ve medikal tedavilere rağmen en önemli önleyici metodun aşı olduğu düşünüldü. Böylelikle aşı üretim çalışmaları çeşitli ülkelerde hız kazandı. Öncelikle Çin de üretilen ve ilk olarak kullanılmaya başlanan corona vac Sinovac Life Sciences (Pekin, Çin) aşısı ülkemizde de 19 Ocak 2021 itibari ile sağlık çalışanlarına yapılmaya başlandı. Aynı tarihlerde huzurevinde kalanlar ve 90 yaş üzerinde olup evinde yaşayanlara, sonrasında sırasıyla 85 yaş ve üzeri, 80 yaş ve üzeri olanlara olmak üzere, Ocak 2021 sonları ve 2021 şubat ayında 65 yaş üzeri kişiler aşılanmaya başlandı.
Bu çalışmada 65 yaş üstü olup Covid 19 tanısı alan hastaların demografik, klinik, laboratuar, görüntüleme yöntemleri ve sonuçları incelendi. Hastaların aşılanma durumları ile hastalığın seyri ve sonuçları arasında ki ilişki araştırıldı.

Abstract:
Despite the various precautions and medical treatments taken in the Covid-19 pandemic, which has affected the whole world since December 2019, the most important preventive method was thought to be vaccination. Thus, vaccine production studies gained momentum in various countries. First of all, the corona vac Sinovac Life Sciences (Beijing, China) vaccine, which was produced in China and started to be used for the first time, started to be administered to healthcare workers as of January 19, 2021 in our country. At the end of January 2021 and in February 2021, people over the age of 65 started to be vaccinated, respectively, those aged 85 and over, and those aged 80 and over, respectively.
In this study, demographic, clinical, laboratory, imaging methods and results of patients over 65 years old and diagnosed with Covid 19 were examined. The relationship between the vaccination status of the patients and the course and outcomes of the disease was investigated.

Keywords

yaş, Covid-19, aşı, Coronovak,

Supporting Institution

destekleyen kurum yoktur

Evaluation of the Efficacy of the CoronaVac Vaccine in COVID-19 Patients Over the Age of 65

Abstract

Objective: In the COVID-19 pandemic, which has affected the whole world, newly produced vaccines have ta-ken their place as the most important agents against the pandemic. The aim of this study is to evaluate the effec-tiveness of the CoronaVac vaccine on the course and outcome of the disease in patients over 65 years of age with a diagnosis of COVID-19.
Material and Method: Before starting this retrospective and observational study, approval was obtained from the local ethics committee of the hospital. PCR positive COVID-19 patients who applied to the emergency de-partment of our hospital with symptoms of COVID-19 and were treated as outpatients or inpatients, and pati-ents aged 65 years and older who were diagnosed with COVID-19 by clinical, laboratory and imaging methods, although PCR was negative, were included. Patients over the age of 65 who did not have sufficient file informa-tion and those who had mRNA vaccine were excluded from the study. Those who received a single dose of vac-cine and those who received two doses of vaccine and were not vaccinated 4 weeks after the second dose were considered unvaccinated. The patients' age, gender, history of smoking and chronic disease, COVID-19 PCR re-sults, whether they were vaccinated, lung imaging findings, laboratory values, treatments they received, whether they were hospitalized or not, were recorded. The vaccinated group and the unvaccinated group were compared in terms of disease severity and outcome.
Results: A total of 420 patients were included in the study. Of the patients, 222 (52.4%) were male and 200 (47.6%) were female. The mean age was calculated as 76.13±7.72 (min 65-max 96). Of the patients, 61 (14.5%) received two doses, and 24.5% (n=103) received only the first dose. CT uptake, noninvasive mechanical ventila-tion and invasive mechanical ventilation were statistically significantly lower in patients who were vaccinated with 2 doses. The mortality rate was found to be statistically significantly higher in unvaccinated patients.
Conclusion: As a result, in this study, it was found that COVID -19 patients who received the CoronaVac vaccine both had less lung involvement and did not result in less mortality. CoronaVac vaccine can reduce the severity and mortality of COVID-19 in patients over 65 years of age

Keywords

Age,, COVID-19,, Vaccine,, CoronoVac,

References

• 1. JEAN, Shio-Shin; LEE, Ping-Ing; HSUEH, Po-Ren. Treatment options for COVID-19: The reality and challenges. Journal of Microbiology, Immunology and Infection, 2020, 53.3: 436-443.
• 2. Hodgson, S. H., Mansatta, K., Mallett, G., Harris, V., Emary, K. R., & Pollard, A. J. (2021). What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. The lancet infectious diseases, 21(2), e26-e35.
• 3. Kashte S, Gulbake A, El-Amin III, S F, Gupta A. (2021). COVID-19 vaccines: rapid development, implications, challenges and future prospects. Human cell, 34(3), 711-733.
• 4. Singh R, Kang A, Luo X, Jeyanathan M, Gillgrass A, Afkhami S, Xing Z. COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development. FASEB J. 2021 Mar;35(3):e21409.
• 5. Han, B., Song, Y., Li, C., Yang, W., Ma, Q., Jiang, Z., ... & Gao, Q. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, 21(12), 1645-1653.
• 6. https://covid19.saglik.gov.tr/TR-6611/covid-19.html. Erişim tarihi: 01.04.2022.
• 7. https://covid19asi.saglik.gov.tr/TR-77707/asi-uygulanacak-grup-siralamasi.html Erişim tarihi: 07.02.2022
• 8. Akpolat T, Uzun O. Reduced mortality rate after coronavac vaccine among healthcare workers. Journal of Infection. 2021;83(2):20-21.
• 9. Chung J. Y., Thone, M. N., & Kwon, Y. J. (2021). COVID-19 vaccines: The status and perspectives in delivery points of view. Advanced drug delivery reviews, 170, 1-25.
• 10. T.C. Sağlık Bakanlığı COVID-19 Aşısı Bilgilendirme Platformu. COVID-19 Aşısı Ulusal Uygulama. Stratejisi. https://covid19asi.saglik.gov.tr/TR-77706/covid-19-asisi-ulusal-uygulamastratejisi.html
• 11. Wu Z., Hu, Y., Xu, M., Chen, Z., Yang, W., Jiang, Z., ... & Yin, W. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, 21(6), 803-812.
• 12. Higdon MM, Wahl B, Jones CB, Rosen JG, Truelove SA, Baidya A, Nande AA, ShamaeiZadeh PA, Walter KK, Feikin DR, Patel MK, Deloria Knoll M, Hill AL. A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. Open Forum Infect Dis. 2022 Apr 18;9(6):ofac138.
• 13. Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ 2021; 374:n2015
• 14. WHO. Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine. https://cdn.who.int/media/docs/defaultsource/immunization/sage/2021/april/5_sage29apr2021_critical-evidence_sinovac.pdf. Erişim tarihi: 06.05.2021.
• 15. Cerqueira-Silva, T., Katikireddi, S. V., de Araujo Oliveira, V., Flores-Ortiz, R., Júnior, J. B., Paixão, E. S., ... & Boaventura, V. S. (2022). Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nature Medicine, 1-6.